EA202090307A2 - TREATMENT OF METABOLIC DISORDERS IN CAT REPRESENTATIVES - Google Patents

TREATMENT OF METABOLIC DISORDERS IN CAT REPRESENTATIVES

Info

Publication number
EA202090307A2
EA202090307A2 EA202090307A EA202090307A EA202090307A2 EA 202090307 A2 EA202090307 A2 EA 202090307A2 EA 202090307 A EA202090307 A EA 202090307A EA 202090307 A EA202090307 A EA 202090307A EA 202090307 A2 EA202090307 A2 EA 202090307A2
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammation
treatment
metabolic disorder
representatives
cat
Prior art date
Application number
EA202090307A
Other languages
Russian (ru)
Other versions
EA202090307A3 (en
Inventor
Дания Бирте Райхе
Зильке Хаг-Диргартен
Лия Дженетте Хеннингс
Заския Клай
Энн М. Трас
Original Assignee
Бёрингер Ингельхайм Ветмедика Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Ветмедика Гмбх filed Critical Бёрингер Ингельхайм Ветмедика Гмбх
Publication of EA202090307A2 publication Critical patent/EA202090307A2/en
Publication of EA202090307A3 publication Critical patent/EA202090307A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Изобретение относится к одному или более ингибиторов SGLT2 или их фармацевтически приемлемым формам для применения в лечении и/или предотвращении метаболического расстройства у животного семейства кошачьих, предпочтительно, где метаболическое расстройство представляет собой одно или более выбранных из группы, которая состоит из кетоацидоза, преддиабета, сахарного диабета типа 1 или типа 2, резистентности к инсулину, ожирения, гипергликемии, нарушенной толерантности к глюкозе, гиперинсулинемии, дислипидемии, дисадипокинемии, субклинического воспаления, системного воспаления, слабо выраженного системного воспаления, печеночного липидоза, атеросклероза, воспаления поджелудочной железы, нейропатии и/или синдрома X (метаболического синдрома) и/или потери функции бета-клеток поджелудочной железы, где достигается и/или поддерживается ремиссия метаболического расстройства, предпочтительно ремиссия диабета.The invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of a metabolic disorder in a feline, preferably, wherein the metabolic disorder is one or more selected from the group consisting of ketoacidosis, prediabetes, sugar type 1 or type 2 diabetes, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, mild systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation / pancreas, or pancreas syndrome X (metabolic syndrome) and / or loss of pancreatic beta cell function, where remission of the metabolic disorder is achieved and / or maintained, preferably diabetes remission.

EA202090307A 2014-10-01 2014-12-15 TREATMENT OF METABOLIC DISORDERS IN Feline EA202090307A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14187228 2014-10-01

Publications (2)

Publication Number Publication Date
EA202090307A2 true EA202090307A2 (en) 2020-05-31
EA202090307A3 EA202090307A3 (en) 2020-07-31

Family

ID=51659520

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090307A EA202090307A3 (en) 2014-10-01 2014-12-15 TREATMENT OF METABOLIC DISORDERS IN Feline

Country Status (2)

Country Link
EA (1) EA202090307A3 (en)
PT (1) PT3862003T (en)

Also Published As

Publication number Publication date
PT3862003T (en) 2024-01-02
EA202090307A3 (en) 2020-07-31

Similar Documents

Publication Publication Date Title
MX2020010832A (en) Treatment of metabolic disorders in feline animals.
CY1126101T1 (en) SGLT2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS IN CANINES
CL2007001972A1 (en) ISOPROPILIC ESTER OF THE ACID 4- [6- (6-METHANOSULPHONYL-2-METHYLPIRIDIN-3-ILAMINO) -5-METHYL-PYRIMIDIN-4-ILOXI] PIPERIDIN-1-CARBOXILIC, METABOLISM MODULATORS; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT METABOLIC DISORDERS.
BR112017005453A8 (en) aminopyridyloxypyrazole, its uses, and pharmaceutical composition.
EA201501032A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND ITS APPLICATIONS
CL2013003025A1 (en) Compounds derived from diaminocarboxamide and diaminocarbonitrile pyrimidines, such as jnk kinase inhibitors; pharmaceutical composition; in vitro inhibition method; and its use in the treatment or prevention of fibrotic liver disorders, diabetes or metabolic syndrome leading to fibrotic liver disorders.
MD4658B1 (en) Apotosis signal-regulating kinase inhibitors
BR112016026264A2 (en) system and method to optimize the startup time of multiple cpus computers.
EP3753936A4 (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
WO2015077503A8 (en) Autotaxin inhibitor compounds
CL2011000101A1 (en) Compounds derived from substituted pyridazine; hedgehog and smo signaling inhibitors; pharmaceutical composition; and use for the treatment of disorders or syndromes associated with hyperproliferative diseases.
PH12015502547A1 (en) Anti-glucagon receptor antibodies and methods of use thereof
BRPI0807749A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD FOR THE PREVENTION, TREATMENT OR IMPROVEMENT OF DISEASE DISEASES OR CONDITIONS, OR ACUTE OR CHRONIC CUTANEAL DISORDER DISORDERS.
WO2014036528A3 (en) Agents useful for treating obesity, diabetes and related disorders
WO2014153009A3 (en) Thiosaccharide mucolytic agents
BR112017020307A2 (en) method to inhibit symptoms associated with alcohol intake, and, pharmaceutical composition
BR112017007025A2 (en) oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder
WO2016068453A8 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
PH12017500795B1 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
BRPI0722057A2 (en) COMPOUND, PRODUCT, PHARMACEUTICAL COMPOSITION, METHOD TO PREVENT OR TREAT SLEEP DISORDER, AND USE OF THE COMPOUND.
WO2016085321A3 (en) Composition comprising a pentose and polyphenolic compound
EA202090307A2 (en) TREATMENT OF METABOLIC DISORDERS IN CAT REPRESENTATIVES
Leman Why Belgium?
BRPI0923492A2 (en) Method for increasing the yield of sucrose in the agricultural production of sugar beet and sugar cane.
BR112018073799A2 (en) method of attenuating a postprandial insulin response, sweetening composition and use of a composition.